Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
Latest Information Update: 07 Sep 2021
At a glance
- Drugs Rabies immune globulin (Primary)
- Indications Rabies
- Focus Adverse reactions
- Sponsors Kamada
- 09 Jun 2021 New trial record
- 02 Jun 2021 According to Kamada and Kedrion Biopharma media release, the U.S. Food and Drug Administration (FDA) has approved a label update for KEDRAB (Rabies Immune Globulin [Human]), establishing the products safety and effectiveness in children based on data from this trial.